Measuring daily activity with a wearable device in amyotrophic lateral sclerosis
Tests a wearable device that tracks daily movement in adults with ALS.
Plain-language title generated from the registry record
Registry title: Continuous Measurement of Activity in Patients With Muscle Pathology and in Control Subjects. ActiSLA Part.
Key facts
- Where
- Liège, BelgiumSee the site
Where in Belgium
- CHR CitadelleLiège, BelgiumTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centre Hospitalier Universitaire de Liege
- Trial code
- NCT04882904
- Record updated
- 5 December 2025
- Original description
ActiSLA is a monocentric academic study. Patients with amyotrophic lateral sclerosis may be included on a voluntary basis. The investigators plan to include a group of approximately 20 patients with ALS.Read full original descriptionShow less
Continuous Measurement of Activity in Patients With Muscle Pathology and in Control Subjects
ActiSLA is a monocentric academic study. Patients with amyotrophic lateral sclerosis may be included on a voluntary basis. The investigators plan to include a group of approximately 20 patients with ALS.
The investigators have planned to assess patient every three months for a year. On each visit, participants will undergo a clinical examination with MRC sum score and Ashworth scores.
They will perform few tests ( 6-minutes walk test (6MWT), dynamometric measure, electromyography, Edinburgh Cognitive and Behavioural ALS Screen ) and will answer to some questionaires (dysphagia handicap scale, ALS-SFR-r).
After each visit, participants will wear Actimyo for one month daily.
Inclusion: Clinically defined or probable diagnosis of ALS according to El Escorial criteria revised with Awaji's electro-diagnostic algorithm; Over 18 years old; Signed informed consent; If patient on Riluzole, the dosage should be stable for 1 month and continued throughout the study period.
Exclusion: Any other previous or present pathology having an impact on motor function; Recent surgery or trauma (less than 6 months) in the upper or lower limbs; Prior neurological, endocrine, infectious, allergic, or chronic or acute inflammatory pathology in the three weeks preceding inclusion; Patients with excessive cognitive disorders, limiting the understanding of task or with apparent communication difficulties hindering data collection; Patients participating in an interventional clinical trial.